Hiroaki Tanaka

7PUBLICATIONS
61CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsRegenerative medicine (incl. stem cells)International arbitrationAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 25, 2026
Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry.

|May 18, 2026
Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

|Feb 05, 2026
Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Hidenori Sakai, Koshiro Sonomoto, Shingo Nakayamada

|Jan 16, 2026
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Koshiro Sonomoto, Shingo Nakayamada, Hidenori Sakai

|Jan 03, 2025
Blood DNA virome associates with autoimmune diseases and COVID-19.

Noah Sasa, Shohei Kojima, Rie Koide

|Sep 17, 2024
Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.

Hidenori Sakai, Yusuke Miyazaki, Shingo Nakayamada

Pageof 2

Frequent Collaborators

7 joint publications

Yoshiya Tanaka

6 joint publications

Shingo Nakayamada

5 joint publications

Hidenori Sakai

5 joint publications

Masanobu Ueno